Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

Abstract

NIH; Alzheimer's Association; American Health Assistance Foundation; Xiamen University Research FundsApolipoprotein E (Apo-E) is a major cholesterol carrier that supports lipid transport and injury repair in the brain. APOE polymorphic alleles are the main genetic determinants of Alzheimer disease (AD) risk: individuals carrying the epsilon 4 allele are at increased risk of AD compared with those carrying the more common epsilon 3 allele, whereas the epsilon 2 allele decreases risk. Presence of the APOE epsilon 4 allele is also associated with increased risk of cerebral amyloid angiopathy and age-related cognitive decline during normal ageing. Apo-E-lipoproteins bind to several cell-surface receptors to deliver lipids, and also to hydrophobic amyloid-beta (A beta) peptide, which is thought to initiate toxic events that lead to synaptic dysfunction and neurodegeneration in AD. Apo-E isoforms differentially regulate A beta aggregation and clearance in the brain, and have distinct functions in regulating brain lipid transport, glucose metabolism, neuronal signalling, neuroinflammation, and mitochondrial function. In this Review, we describe current knowledge on Apo-E in the CNS, with a particular emphasis on the clinical and pathological features associated with carriers of different Apo-E isoforms. We also discuss A beta-dependent and A beta-independent mechanisms that link Apo-E4 status with AD risk, and consider how to design effective strategies for AD therapy by targeting Apo-E. Liu, C.-C. et al. Nat. Rev. Neurol. 9, 106-118 (2013); published online 8 January 2013; doi:10.1038/nrneurol.2012.26